@article {47025,
	title = {Short review of synthetic routes for the antiepileptic drug (R)-lacosamide},
	journal = {Organic Process Research \& Development},
	volume = {24},
	year = {2020},
	month = {JAN},
	pages = {17-24},
	type = {Review},
	abstract = {<p>The disease epilepsy affects people of all ages and is due to a chronic neurological disorder in the brain. According to a report by the World Health Organization, epilepsy is one of the most common global neurological diseases. (R)-Lacosamide (Vimpat) was introduced by UCB Pharma in 2008 for the treatment of partial-onset seizures in patients suffering from epilepsy. This review summarizes all of the available synthetic strategies reported for (R)-lacosamide, which will help medicinal chemists in the further development of its synthesis.</p>
},
	keywords = {antiepileptic drug, epilepsy, lacosamide, serine derivative, synthesis},
	issn = {1083-6160},
	doi = {10.1021/acs.oprd.9b00373},
	author = {Aratikatla, Eswar K. and Bhattacharya, Asish K.}
}
@article {49043,
	title = {Short review on the synthetic routes for the antiepileptic drug (S)-levetiracetam},
	journal = {Organic Process Research and Development },
	volume = {28},
	year = {2024},
	month = {MAR },
	pages = {924-936},
	type = {Review},
	abstract = {<p>
	Epilepsy is a chronic disorder characterized by recurrent unpredictable seizures. Levetiracetam (Keppra) was introduced by UCB for the treatment of partial onset seizures in patients above 16 years of age diagnosed with epilepsy. This review reports synthetic strategies available for the synthesis of (S)-levetiracetam and will certainly aid the quest for the development of new routes for its synthesis.</p>
},
	keywords = {antiepileptic drug, butyrolactam, epilepsy, levetiracetam, synthesis},
	issn = {1083-6160},
	doi = {10.1021/acs.oprd.4c00002},
	author = {Paul, Sayantan and Bhattacharya, Asish K.}
}
